

2015 Strategies in the UK Hospital Tumor Marker Testing Market

<https://marketpublishers.com/r/2094BAA10C3EN.html>

Date: February 2015

Pages: 527

Price: US\$ 3,080.00 (Single User License)

ID: 2094BAA10C3EN

Abstracts

This new report from VPGMarketResearch contains 527 pages, 37 tables, and presents a comprehensive analysis of the UK hospital tumor marker testing market, including:

Major issues pertaining to the UK hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Test volume and sales forecasts for 40 tumor markers performed in UK hospitals.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.

Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 527 pages and 37 tables

Contents

Introduction

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

1. BREAST CANCER
2. LUNG CANCER
3. COLON AND RECTUM CANCER
4. PROSTATE CANCER
5. STOMACH CANCER
6. LEUKEMIA
7. LYMPHOMA
8. ORAL CANCER
9. SKIN CANCER
10. UTERINE CANCER
11. OVARIAN CANCER
12. BLADDER CANCER

B. Major Current And Emerging Cancer Diagnostic Tests

1. INTRODUCTION
2. TUMOR MARKER CLASSIFICATION
3. ACTH
4. ALPHA-FETOPROTEIN (AFP)
5. BETA-2 MICROGLOBULIN
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. CALCITONIN
10. CARCINOEMBRIONIC ANTIGEN (CEA)
11. ESTROGEN AND PROGESTERONE RECEPTORS
12. FERRITIN
13. GASTRIN
14. HUMAN CHORIONIC GONADOTROPIN (HCG)
15. INSULIN
16. NSE
17. OCCULT BLOOD
18. PAP SMEAR/HPV
19. PROSTATIC ACID PHOSPHATASE (PAP)

- 20. PROSTATE-SPECIFIC ANTIGEN (PSA)
- 21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
- 22. T AND B LYMPHOCYTES
- 23. TDT
- 24. THYROGLOBULIN
- 25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
- 26. BIOCHEMICAL TUMOR MARKERS
 - ADA
 - B-Protein
 - PNP
 - 5'-Nucleotidase
- 27. ONCOGENES
 - Abl/abl-bcr
 - AIB1
 - BCL-2
 - BRCA1
 - CD44
 - C-fos
 - C-myb
 - C-myc
 - CYP-17
 - Erb-B
 - HPC1
 - N-myc
 - P40
 - P51
 - P53
 - PIK3CA
 - PTI-1
 - Ras
 - Reg
 - Sis
 - Src
- 28. POLYPEPTIDE GROWTH FACTORS
 - Basic Fibroblast Growth Factor
 - Beta-TGF
 - Cachectin (TNT)
 - Calmodulin
 - ECFR

Nerve Growth Factor (NGF)
Epidermal Growth Factor (EGF)
Ornithine Decarboxylase
Transferrin
Transforming Growth Factor-Alpha
29. ECTOPIC HORMONES
30. COLONY STIMULATING FACTORS
31. LYMPHOKINES
Alpha-Interferon
B Cell Growth Factors
B Cell Growth Factor (BCGF)
Gamma-Interferon
Interleukin-1 (IL-1)
Macrophage Activating Factor
32. IMMUNOHISTOCHEMICAL STAINS
33. EMERGING TUMOR MARKERS
N-Acetylglucosamine
Actin
Alpha-Actin
Antineuronal Antibodies
7B2
B72.3
Bax
BCD-F9
BLCA-4
Blood Group Antigens A,B,H
CA
CA 72-4/TAG-72
CA
CA-242
CA-549
CAM
CAR-3
Cathepsin-D
Chromogranin A and B
Cluster 1 Antigen
Cluster-5/5A Antigen
CTA
CU18

DR-70
DU-PAN-2
Endometrial Bleeding Associated Factor
Endostatin
Epithelial Membrane Antigen
Feulgen Hydrolysis
Fibronectin
FSH
(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15
Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor
Myosin
NEA-130
NMP22
OA-519
Opioid Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL
Selectin
Sialic Acid
Sialyl SSEA-1/SLX
SN10
Somatostatin
TA-90
TABA
Tachykinin
TAG
TPS
Troponin
Tubulin
VCAM
VEGF
Villen
C. Instrumentation Review And
Market Needs
1. ABBOTT AXSYM
2. ABBOTT ARCHITECT C4000
3. ABBOTT ARCHITECT I200 SERIES
4. ABBOTT ARCHITECT CI820 SYSTEM
5. BECKMAN COULTER UNICEL SERIES
6. BECKMAN COULTER ACCESS
7. BINDING SITE ESP600

8. BIOMERIEUX MINI VIDAS
 9. CAROLINA CHEMISTRIES BIOLIS 24I
 10. DIASORIN LIAISON
 11. HORIBA ABX PENTRA
 12. INVERNESS DS2
 13. J&J VITROS ECI/ECIQ
 14. J&J VITROS 3600
 15. J&J VITROS 5600
 16. OLYMPUS AU5400
 17. OLYMPUS AU3000I
 18. OLYMPUS AU2700
 19. ROCHE MODULAR ANALYTICS
 20. ROCHE COBAS INTEGRA
 21. ROCHE COBAS INTEGRA 40 PLUS
 22. ROCHE ELECSYS
 23. ROCHE COBAS C311
 24. SIEMENS ADVIA CENTAUR
 25. SIEMENS DIMENSION
 26. SIEMENS DIMENSION RXL MAX
 27. SIEMENS DIMENSION VISTA
 28. SIEMENS IMMULITE
 29. SIEMENS STRATUS
 30. TOSOH AIA-SERIES
 31. VITAL DIAGNOSTICS ATAC 8000
 32. VITAL DIAGNOSTICS ENVOY
- D. Current and Emerging Technologies
1. MONOCLONAL AND POLYCLONAL ANTIBODIES
 2. IMMUNOASSAYS
 - a. Technological Principle
 - b. Radioimmunoassay (RIA)
 - c. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
- d. Fluorescent Immunoassays
 - e. Luminescence
- Chemiluminescence

Bioluminescence

f. Latex Agglutination

g. Immunoprecipitation

H. Affinity Chromatography

e. Liposome Flow-Injection Immunoassay

3. MOLECULAR DIAGNOSTICS

a. Technology Overview

b. Amplification Methods

PCR

DAP-PCR

Immuno-PCR

QC-PCR

CAR

DNA

HPA

LCR

NASBA

QBR

SDA

3 SR, and others

4. CHROMOSOME ANALYSIS

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. ARTIFICIAL INTELLIGENCE

6. FLOW CYTOMETRY

7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)

8. BIOSENSORS

9. COMPETING/COMPLEMENTING TECHNOLOGIES

a. CT

b. MRI

c. NMR

d. PET

e. Photonics Spectroscopy

E. Personal Testing

U.K.

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers

MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
- 1. MARKETING APPROACHES
- 2. PRODUCT COMPLEXITY
- 3. CUSTOMER PREFERENCE
- 4. ESTABLISHED SUPPLIERS
- 5. EMERGING SUPPLIERS
- 6. MAJOR TYPES OF DISTRIBUTORS
- 7. MARKET SEGMENTATION FACTOR

POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints

G. Decentralized Testing Market Challenges

COMPETITIVE PROFILES

Abbott

AdnaGen

Applied Gene Technologies

Arca

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

Cepheid

Correlogic Systems

Dako

Decode

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Gen-Probe

Guided Therapeutics

Hologic

Ipsogen

Kreatech

Kyowa Medex

Life Technologies

Mackay Life Sciences

Myriad Genetics

Nanogen Elitech

OncoLab

Otho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD
Qiagen
Radiant Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

APPENDIXES

Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications

Appendix II: Assumed Currency Exchange Rates

List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table :U.K., Hospital Cancer Diagnostic Test Volume and Sales Forecast by Market Segment

U.K., Estimated Cancer Death Rates Per 100,00 Population

U.K., Hospital Laboratories Performing Cancer Diagnostic Tests

U.K., Hospital Laboratories Performing Cancer Diagnostic Tests by Bed Size

U.K., Hospital Laboratories Major Cancer Diagnostic Test Volume Forecast by Test

U.K., Hospital Laboratories Cancer Diagnostics Sales Forecast by Test

U.K., Total Cancer Diagnostics Sales By Major Supplier
U.K., CEA Testing Market Diagnostics Sales by Major Supplier
U.K., PSA Testing Market Diagnostics Sales by Major Supplier

I would like to order

Product name: 2015 Strategies in the UK Hospital Tumor Marker Testing Market

Product link: <https://marketpublishers.com/r/2094BAA10C3EN.html>

Price: US\$ 3,080.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2094BAA10C3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970